Is MaxCyte, Inc. overvalued or undervalued?

As of 22 March 2022, the valuation grade for MaxCyte, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15 and a concerning EV to EBITDA ratio of -2.00. Additionally, the Return on Capital Employed (ROCE) stands at a negative 80.39%, further highlighting the company's struggles in generating returns.
In comparison to its peers, MaxCyte, Inc. has a significantly lower EV to EBITDA ratio of -0.5242 compared to Voyager Therapeutics, Inc. at -0.2378 and bluebird bio, Inc. at -0.7970, suggesting that it is less favorably positioned within the industry. Furthermore, the stock has underperformed relative to the S&P 500, with a year-to-date return of -61.06% compared to the index's 12.22%, reinforcing the notion of its overvaluation amidst a challenging market environment.